Anavex Finishes Dosing In Two Blarcamesine Studies Of 65 And 8 Healthy Volunteers

Preliminary results showed no serious adverse events in either study, and the company says full analysis is still under way.

Share
Anavex Finishes Dosing In Two Blarcamesine Studies Of 65 And 8 Healthy Volunteers

Anavex Life Sciences said in an 8-K filed Tuesday that the clinical portion of two healthy-volunteer studies of its Alzheimer's drug candidate blarcamesine is complete. Based on preliminary observations, no serious adverse events were reported in either one.

What the press release says

The drug-drug interaction study was fully enrolled with 65 participants, all of whom received 30 mg of blarcamesine. Its last participant finished at the end of September.

The second study, which tracks how the body absorbs, distributes, metabolizes and excretes the drug, enrolled 8 participants, also at 30 mg. Its last participant finished in mid-October.

Full safety and pharmacokinetic analysis (how the drug moves through the body) is ongoing for both, the company said. Both enrolled healthy volunteers, and Anavex says the data are critical for the Alzheimer's program and expected to support its Rett syndrome and Fragile X programs.

What it changes

The studies address clinical pharmacology data the FDA recommended, a recommendation Anavex said matches feedback from the European Medicines Agency. Interim CEO Terrie Kellmeyer, Ph.D., said completion advances "the clinical pharmacology data package recommended by the FDA, which we expect to benefit our ongoing core programs."

The release also notes that the FDA cleared the company's Fragile X application, announced October 15. That gives Anavex open investigational drug applications in all three core indications: Alzheimer's disease, Rett syndrome and Fragile X syndrome.

For Rett syndrome, the company has an FDA-aligned protocol for an adult Phase 3 study, and start-up activities are underway. Both Rett and Fragile X have Orphan Drug Designation from the FDA.

Anavex shares closed at $1.36 in Tuesday's regular session, up 8.80%, before the company filed after the close.

What to watch

The FDA granted Anavex a meeting in November to discuss adding pediatric participants to the Phase 3 Rett study, as previously announced on September 9, 2026.

Anavex has not yet released any results from the full safety and pharmacokinetic analysis; the next dated event is the November FDA meeting on children in the Rett study.

Sources

More on Anavex Life Sciences

All Anavex Life Sciences (AVXL) coverage →